These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 8528268)

  • 1. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
    Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
    Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
    Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype.
    Daly AK; Fairbrother KS; Andreassen OA; London SJ; Idle JR; Steen VM
    Pharmacogenetics; 1996 Aug; 6(4):319-28. PubMed ID: 8873218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
    Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
    DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.
    Saxena R; Shaw GL; Relling MV; Frame JN; Moir DT; Evans WE; Caporaso N; Weiffenbach B
    Hum Mol Genet; 1994 Jun; 3(6):923-6. PubMed ID: 7951238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F; Meyer UA
    Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
    Dahl ML; Johansson I; Palmertz MP; Ingelman-Sundberg M; Sjöqvist F
    Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
    Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
    Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype.
    Panserat S; Mura C; Gérard N; Vincent-Viry M; Galteau MM; Jacoz-Aigrain E; Krishnamoorthy R
    Br J Clin Pharmacol; 1995 Oct; 40(4):361-7. PubMed ID: 8554938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.
    Mura C; Gerard N; Vincent-Viry M; Galteau MM; Jacqz-Aigrain E; Krishnamoorthy R
    Br J Clin Pharmacol; 1993 Feb; 35(2):161-5. PubMed ID: 8095148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.
    Broly F; Marez D; Sabbagh N; Legrand M; Millecamps S; Lo Guidice JM; Boone P; Meyer UA
    Pharmacogenetics; 1995 Dec; 5(6):373-84. PubMed ID: 8747409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
    Daly AK; Armstrong M; Monkman SC; Idle ME; Idle JR
    Pharmacogenetics; 1991 Oct; 1(1):33-41. PubMed ID: 1688241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype.
    Marez D; Sabbagh N; Legrand M; Lo-Guidice JM; Boone P; Broly F
    Pharmacogenetics; 1995 Oct; 5(5):305-11. PubMed ID: 8563771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene.
    Steen VM; Molven A; Aarskog NK; Gulbrandsen AK
    Hum Mol Genet; 1995 Dec; 4(12):2251-7. PubMed ID: 8634695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.
    Kimura S; Umeno M; Skoda RC; Meyer UA; Gonzalez FJ
    Am J Hum Genet; 1989 Dec; 45(6):889-904. PubMed ID: 2574001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.
    Evans WE; Relling MV; Rahman A; McLeod HL; Scott EP; Lin JS
    J Clin Invest; 1993 May; 91(5):2150-4. PubMed ID: 8098046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
    Johansson I; Oscarson M; Yue QY; Bertilsson L; Sjöqvist F; Ingelman-Sundberg M
    Mol Pharmacol; 1994 Sep; 46(3):452-9. PubMed ID: 7935325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population.
    Masimirembwa CM; Johansson I; Hasler JA; Ingelman-Sundberg M
    Pharmacogenetics; 1993 Dec; 3(6):275-80. PubMed ID: 7908586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population.
    Kondo I; Yonaha M; Okano K; Gonzalez FJ; Kanazawa I
    Pharmacogenetics; 1991 Dec; 1(3):161-4. PubMed ID: 1688247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.